The effect of dietary supplementation of sage plant extract and Enterocin M on the mucus in the the small intestine and caecum in rabbits.

The aim of this study was to determine the beneficial effect of natural substances - enterocin M (Ent M; the proteinaceous substance produced by Enterococcus faecium CCM8558) and sage plant ( Salvia officinalis L.) extract on the production of mucus in the rabbits small intestine and caecum. Sixty four post-weaned rabbits (meat line M91) were divided into three experimental groups (EG - Ent M; SG - sage extract; ESG - combination Ent M with sage extract) and control group (CG). The experiment lasted for 35 days, the natural substances were administered during the first 21 days, Ent M in EG/ESG, sage extract in SG/ESG. The beneficial effect on mucus production quantity occured in the duodenum (p⟨0.001) and jejunum (p⟨0.01) in ESG compared to that found in CG on day 21, the prolonged effect in EG in the duodenum (p⟨0.001) compared to that observed in CG at the end of the experiment and to that in EG on day 21. The novelty of the study is in the application and monitoring the effect of non-rabbit-derived probiotic strain ( Enterococcus faecium CCM8558) bacteriocin - Enterocin M and sage plant extract on mucus quantity (expressed in gram) in different segments of the rabbit small intestine as well as the caecum. The results obtained indicate that supplementation of selected natural substances in the feed has the potent stimulatory effects on mucus production in the rabbit small intestine.

[Effect of polymorphisms of cytochrome P450 and apolipoprotein E genes on therapeutic efficacy of statins].

Statins are widely used in clinical practice for lowering of levels of atherogenic blood plasma lipids and treatment of atherosclerosis. Variability of response of the body to these drugs might be determined by genetic factors (gene polymorphisms) related to metabolism of drugs. Among them central place belongs to enzymes of subfamily 3A of cytochrome P450 (CYP). In this review we present results of studies assessing effect of various allele variants of CYP3A4 and CYP3A5 on efficacy and tolerability of atorvastatin, lovastatin,, and simvastatin in different populations of patients. We also present data on populational frequency of genetic polymorphisms under study. In addition we cover the problem of possible influence of apoE genotype on efficacy of statins. The available data do not allow yet to recommend pharmacogenetic testing for wide clinical practice.